{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:32:31Z","timestamp":1785717151768,"version":"3.56.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01 DP006491"],"award-info":[{"award-number":["U01 DP006491"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01 DP006491"],"award-info":[{"award-number":["U01 DP006491"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes, osteoporosis, and infections. Preventive services are particularly important in patients with SLE to mitigate the aforementioned risks. We aimed to evaluate the trends of preventive services utilization in patients with systemic lupus erythematosus, compared with non-SLE population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All \u226519-year-old patients in the Lupus Midwest Network (LUMEN) registry, a population-based cohort, with SLE on January 1, 2015, were included and matched (1:1) by sex, age, race, and county to non-SLE comparators. Among both groups, we compared the rates of screenings for breast and cervical cancer, hypertension, hyperlipidemia, diabetes mellitus, and osteoporosis as well as immunizations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 440 SLE patients and 430 non-SLE comparators. The probability of breast cancer screening among women with SLE was similar to comparators (hazard ratio [HR] 1.09, 95% CI 0.85\u20131.39), while cervical cancer screening was lower (HR 0.75, 95% CI 0.58\u20130.96). Hypertension screening was higher among patients with SLE (HR 1.35, 95% CI 1.13\u20131.62); however, hyperlipidemia screening was similar to comparators (HR 1.16, 95% CI 0.96\u20131.41). Diabetes and osteoporosis screenings were more likely to be performed for SLE patients than for comparators (HR 2.46, 95% CI 2.11\u20132.87; and HR 3.19, 95% CI 2.31\u20134.41; respectively). Influenza and pneumococcal immunizations were higher among SLE patients (HR 1.31, 95% CI 1.12\u20131.54; and HR 2.06, 95% CI 1.38\u20133.09; respectively), while zoster vaccination was similar (HR 1.17, 95% CI 0.81\u20131.69).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The trends of utilization of preventive services by SLE patients vary according to screening or vaccine compared with the general population. Considering these differences, we demonstrate an opportunity for improvement, particularly in cervical cancer, hyperlipidemia, and osteoporosis screenings and vaccinations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02878-8","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T07:03:44Z","timestamp":1662015824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-7603","authenticated-orcid":false,"given":"Baptiste","family":"Chevet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6077-8899","authenticated-orcid":false,"given":"Gabriel","family":"Figueroa-Parra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Hocaoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley-Ann","family":"Osei-Onomah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassondra A.","family":"Hulshizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-8774","authenticated-orcid":false,"given":"Tina M.","family":"Gunderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0546-6742","authenticated-orcid":false,"given":"Kamil E.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt J.","family":"Greenlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5847-7475","authenticated-orcid":false,"given":"Cynthia S.","family":"Crowson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1749-5719","authenticated-orcid":false,"given":"Al\u00ed","family":"Duarte-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"issue":"1","key":"2878_CR1","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","volume":"2","author":"A Kaul","year":"2016","unstructured":"Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2(1):16039.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2878_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605\u201314.","journal-title":"Nat Immunol"},{"issue":"9","key":"2878_CR3","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2878_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3899\/jrheum.160214","volume":"45","author":"HL Chen","year":"2018","unstructured":"Chen HL, Shen LJ, Hsu PN, Shen CY, Hall SA, Hsiao FY. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"2878_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1093\/rheumatology\/keu412","volume":"54","author":"CS Yee","year":"2015","unstructured":"Yee CS, Su L, Toescu V, Hickman R, Situnayake D, Bowman S, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836\u201343.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2878_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee YH, Choi SJ, Ji JD, Song GG. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25(7):727\u201334.","journal-title":"Lupus"},{"issue":"6","key":"2878_CR7","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2878_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/acr.22808","volume":"68","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, Thompson K, Skedgel C. Utilization of ambulatory physician encounters, emergency room visits, and hospitalizations by systemic lupus erythematosus patients: a 13-year population health study. Arthritis Care Res. 2016;68(8):1128\u201334.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2878_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1177\/0961203312474087","volume":"22","author":"DE Furst","year":"2013","unstructured":"Furst DE, Clarke A, Fernandes AW, Bancroft T, Gajria K, Greth W, et al. Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus. 2013;22(3):268\u201378.","journal-title":"Lupus"},{"issue":"1","key":"2878_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/acr.24095","volume":"73","author":"CH Feldman","year":"2021","unstructured":"Feldman CH, Speyer C, Ashby R, BLB, Bhattacharyya S, Chakravarty E, et al. Development of a set of lupus-specific, ambulatory care-sensitive, potentially preventable adverse conditions: a Delphi consensus study. Arthritis Care Res. 2021;73(1):146\u201357.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"2878_CR11","first-page":"613","volume":"56","author":"H Wadstrom","year":"2017","unstructured":"Wadstrom H, Arkema EV, Sjowall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56(4):613\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2878_CR12","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.11296","volume":"48","author":"IN Bruce","year":"2003","unstructured":"Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003;48(11):3159\u201367.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2878_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.20568","volume":"64","author":"IE Bultink","year":"2012","unstructured":"Bultink IE. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. 2012;64(1):2\u20138.","journal-title":"Arthritis Care Res"},{"issue":"2","key":"2878_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001041","volume":"5","author":"V Furer","year":"2019","unstructured":"Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041.","journal-title":"RMD Open"},{"issue":"3","key":"2878_CR15","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/ar3011","volume":"12","author":"J Yazdany","year":"2010","unstructured":"Yazdany J, Tonner C, Trupin L, Panopalis P, Gillis JZ, Hersh AO, et al. Provision of preventive health care in systemic lupus erythematosus: data from a large observational cohort study. Arthritis Res Ther. 2010;12(3):R84.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2878_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.semarthrit.2013.04.003","volume":"43","author":"C Drenkard","year":"2013","unstructured":"Drenkard C, Rask KJ, Easley KA, Bao G, Lim SS. Primary preventive services in patients with systemic lupus erythematosus: study from a population-based sample in southeast U.S. Semin Arthritis Rheum. 2013;43(2):209\u201316.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"2878_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/acr.23574","volume":"71","author":"SK Chen","year":"2019","unstructured":"Chen SK, Barbhaiya M, Fischer MA, Guan H, Lin TC, Feldman CH, et al. Lipid testing and statin prescriptions among Medicaid recipients with systemic lupus erythematosus or diabetes mellitus and the general Medicaid population. Arthritis Care Res. 2019;71(1):104\u201315.","journal-title":"Arthritis Care Res"},{"key":"2878_CR18","doi-asserted-by":"crossref","unstructured":"Sim JJL, Lim CC. Influenza Vaccination in Systemic Lupus Erythematosus: Efficacy, Effectiveness, Safety, Utilization, and Barriers. Am J Med.\u00a02022;135(3):286-296 e289.","DOI":"10.1016\/j.amjmed.2021.08.038"},{"issue":"9","key":"2878_CR19","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/aje\/kwq482","volume":"173","author":"JL St Sauver","year":"2011","unstructured":"St Sauver JL, Grossardt BR, Yawn BP, Melton LJ 3rd, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol. 2011;173(9):1059\u201368.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"2878_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.mayocp.2011.11.009","volume":"87","author":"JL St Sauver","year":"2012","unstructured":"St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ 3rd, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clin Proc. 2012;87(2):151\u201360.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2878_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/ije\/dyx268","volume":"47","author":"WA Rocca","year":"2018","unstructured":"Rocca WA, Grossardt BR, Brue SM, Bock-Goodner CM, Chamberlain AM, Wilson PM, et al. Data resource profile: expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP). Int J Epidemiol. 2018;47(2):368\u2013368j.","journal-title":"Int J Epidemiol"},{"key":"2878_CR22","doi-asserted-by":"crossref","unstructured":"Duarte-Garcia A, Hocaoglu M, Osei-Onomah SA, Dabit JY, Giblon RE, Helmick CG, Crowson CS. Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study. Rheumatology (Oxford).\u00a02022;61(6):2424-31.","DOI":"10.1093\/rheumatology\/keab807"},{"key":"2878_CR23","doi-asserted-by":"crossref","unstructured":"Valenzuela-Almada MO, Hocaoglu M, Dabit JY, Osei-Onomah SA, Basiaga ML, Orandi AB, Giblon RE, Barbour KE, Crowson CS, Duarte-Garcia A. Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Care Res (Hoboken).\u00a02022;74(5):728-32.","DOI":"10.1002\/acr.24827"},{"key":"2878_CR24","doi-asserted-by":"publisher","unstructured":"Duarte-Garcia A, Hocaoglu M, Valenzuela-Almada M, Osei-Onomah SA, Dabit JY, Sanchez-Rodriguez A, et al. Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222276.","DOI":"10.1136\/annrheumdis-2022-222276"},{"issue":"9","key":"2878_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2019;71(9):1400\u201312.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2878_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0618","volume":"3","author":"SS Kurani","year":"2020","unstructured":"Kurani SS, McCoy RG, Lampman MA, Doubeni CA, Finney Rutten LJ, Inselman JW, et al. Association of neighborhood measures of social determinants of health with breast, cervical, and colorectal cancer screening rates in the US midwest. JAMA Netw Open. 2020;3(3):e200618.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2878_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"10","key":"2878_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.7326\/0003-4819-151-10-200911170-00008","volume":"151","author":"USPSTF","year":"2009","unstructured":"USPSTF. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151(10):716\u201326 W-236.","journal-title":"Ann Intern Med"},{"issue":"4","key":"2878_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.7326\/M15-2886","volume":"164","author":"AL Siu","year":"2016","unstructured":"Siu AL, USPSTF. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164(4):279\u201396.","journal-title":"Ann Intern Med"},{"issue":"12","key":"2878_CR30","doi-asserted-by":"publisher","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","volume":"156","author":"VA Moyer","year":"2012","unstructured":"Moyer VA, USPSTF. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156(12):880\u201391 W312.","journal-title":"Ann Intern Med"},{"issue":"7","key":"2878_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2018.10897","volume":"320","author":"SJ Curry","year":"2018","unstructured":"USPSTF, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674\u201386.","journal-title":"JAMA"},{"issue":"11","key":"2878_CR32","doi-asserted-by":"publisher","first-page":"783","DOI":"10.7326\/0003-4819-147-11-200712040-00009","volume":"147","author":"USPSTF","year":"2007","unstructured":"USPSTF. Screening for high blood pressure: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2007;147(11):783\u20136.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2878_CR33","doi-asserted-by":"publisher","first-page":"778","DOI":"10.7326\/M15-2223","volume":"163","author":"AL Siu","year":"2015","unstructured":"Siu AL, USPSTF. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(10):778\u201386.","journal-title":"Ann Intern Med"},{"key":"2878_CR34","volume-title":"Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review","author":"M Helfand","year":"2008","unstructured":"Helfand M, Carson S: U.S. Preventive Services Task Force evidence syntheses, formerly systematic evidence reviews. In:  Screening for Lipid Disorders in Adults: Selective Update of 2001 US Preventive Services Task Force Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008."},{"key":"2878_CR35","unstructured":"USPSTF. Lipid disorders in adults (cholesterol, dyslipidemia): screening. 2013.https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lipid-disorders-in-adults-cholesterol-dyslipidemia-screening-2008#fullrecommendationstart. Accessed 2 Nov 2021."},{"issue":"19","key":"2878_CR36","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2016.15450","volume":"316","author":"K Bibbins-Domingo","year":"2016","unstructured":"USPSTF, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016;316(19):1997\u20132007.","journal-title":"JAMA"},{"issue":"11","key":"2878_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.7326\/M15-2345","volume":"163","author":"AL Siu","year":"2015","unstructured":"Siu AL, USPSTF. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163(11):861\u20138.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2878_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"USPSTF","year":"2011","unstructured":"USPSTF. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154(5):356\u201364.","journal-title":"Ann Intern Med"},{"issue":"24","key":"2878_CR39","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"SJ Curry","year":"2018","unstructured":"USPSTF, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(24):2521\u201331.","journal-title":"JAMA"},{"issue":"30","key":"2878_CR40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.15585\/mmwr.mm6430a3","volume":"64","author":"LA Grohskopf","year":"2015","unstructured":"Grohskopf LA, Sokolow LZ, Olsen SJ, Bresee JS, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep. 2015;64(30):818\u201325.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"2878_CR41","first-page":"1102","volume":"59","author":"CDC, ACIP","year":"2010","unstructured":"CDC, ACIP. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59(34):1102\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"46","key":"2878_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","volume":"68","author":"A Matanock","year":"2019","unstructured":"Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069\u201375.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"33","key":"2878_CR43","first-page":"729","volume":"63","author":"CM Hales","year":"2014","unstructured":"Hales CM, Harpaz R, Ortega-Sanchez I, Bialek SR. Centers for Disease C, Prevention: Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63(33):729\u201331.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"2878_CR44","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","volume":"67","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2878_CR45","first-page":"45","volume":"33","author":"SR Bernatsky","year":"2006","unstructured":"Bernatsky SR, Cooper GS, Mill C, Ramsey-Goldman R, Clarke AE, Pineau CA. Cancer screening in patients with systemic lupus erythematosus. J Rheumatol. 2006;33(1):45\u20139.","journal-title":"J Rheumatol"},{"issue":"12","key":"2878_CR46","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/acr.24414","volume":"73","author":"S Bruera","year":"2021","unstructured":"Bruera S, Lei X, Zogala R, Pundole X, Zhao H, Giordano SH, et al. Cervical cancer screening in women with systemic lupus erythematosus. Arthritis Care Res. 2021;73(12):1796\u2013803.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"2878_CR47","first-page":"493","volume":"30","author":"A Al-Herz","year":"2003","unstructured":"Al-Herz A, Ensworth S, Shojania K, Esdaile JM. Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol. 2003;30(3):493\u20136.","journal-title":"J Rheumatol"},{"issue":"2","key":"2878_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/acr.24446","volume":"74","author":"G Schmajuk","year":"2022","unstructured":"Schmajuk G, Li J, Evans M, Anastasiou C, Kay JL, Yazdany J. Quality of care for patients with systemic lupus erythematosus: data from the American College of Rheumatology RISE registry. Arthritis Care Res. 2022;74(2):179\u201386.","journal-title":"Arthritis Care Res"},{"key":"2878_CR49","doi-asserted-by":"publisher","unstructured":"Albrecht K, Redeker I, Aringer M, Marschall U, Strangfeld A, Callhoff J. Comorbidity and healthcare utilisation in persons with incident systemic lupus erythematosus followed for 3 years after diagnosis: analysis of a claims data cohort. Lupus Sci Med. 2021;8(1):e000526. https:\/\/doi.org\/10.1136\/lupus-2021-000526.","DOI":"10.1136\/lupus-2021-000526"},{"issue":"3","key":"2878_CR50","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.semarthrit.2010.01.001","volume":"40","author":"KL Demas","year":"2010","unstructured":"Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH. Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. Semin Arthritis Rheum. 2010;40(3):193\u2013200.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2878_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0961203312470186","volume":"22","author":"EF Chakravarty","year":"2013","unstructured":"Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22(3):238\u201344.","journal-title":"Lupus"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02878-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T08:10:46Z","timestamp":1662019846000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02878-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2878"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02878-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"23 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review boards of the Mayo Clinic (20-006485) and Olmsted Medical Center (036-OMC-20). Any identified subjects who did not provide consent for use of their medical records for research purposes were excluded from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}